Publication | Open Access

Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial

Clinical SymptomsAllergyAntibioticsAtopic DermatitisSkin AllergyClinical DermatologyDermatologyPhase 2MedicineAntimicrobial Resistance